Riverbridge Partners LLC Has $100.01 Million Stock Holdings in Privia Health Group, Inc. (NASDAQ:PRVA)

Riverbridge Partners LLC increased its position in shares of Privia Health Group, Inc. (NASDAQ:PRVA - Free Report) by 8.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,342,385 shares of the company's stock after buying an additional 348,852 shares during the quarter. Privia Health Group accounts for 1.3% of Riverbridge Partners LLC's portfolio, making the stock its 23rd biggest holding. Riverbridge Partners LLC owned approximately 3.68% of Privia Health Group worth $100,005,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the company. Ensign Peak Advisors Inc lifted its stake in Privia Health Group by 1.3% during the first quarter. Ensign Peak Advisors Inc now owns 31,290 shares of the company's stock worth $864,000 after purchasing an additional 400 shares during the period. Amalgamated Bank lifted its stake in Privia Health Group by 5.8% during the fourth quarter. Amalgamated Bank now owns 7,638 shares of the company's stock worth $173,000 after purchasing an additional 418 shares during the period. American International Group Inc. lifted its stake in Privia Health Group by 2.3% during the fourth quarter. American International Group Inc. now owns 21,670 shares of the company's stock worth $492,000 after purchasing an additional 487 shares during the period. Covestor Ltd lifted its stake in Privia Health Group by 8.3% during the third quarter. Covestor Ltd now owns 6,703 shares of the company's stock worth $154,000 after purchasing an additional 514 shares during the period. Finally, Yousif Capital Management LLC lifted its stake in Privia Health Group by 1.1% during the third quarter. Yousif Capital Management LLC now owns 52,065 shares of the company's stock worth $1,197,000 after purchasing an additional 574 shares during the period. 94.48% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. Evercore ISI cut their price target on shares of Privia Health Group from $26.00 to $25.00 and set an "outperform" rating for the company in a research note on Wednesday, February 28th. JPMorgan Chase & Co. cut their target price on shares of Privia Health Group from $38.00 to $30.00 and set an "overweight" rating for the company in a research note on Wednesday, March 6th. Truist Financial cut their target price on shares of Privia Health Group from $32.00 to $28.00 and set a "buy" rating for the company in a research note on Thursday, February 29th. Canaccord Genuity Group cut their target price on shares of Privia Health Group from $41.00 to $37.00 and set a "buy" rating for the company in a research note on Tuesday, March 19th. Finally, Barclays started coverage on shares of Privia Health Group in a research note on Wednesday, March 6th. They issued an "equal weight" rating and a $22.00 target price for the company. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $28.58.

Privia Health Group Stock Up 0.7 %

PRVA stock traded up $0.13 during trading on Thursday, hitting $18.38. The company had a trading volume of 762,029 shares, compared to its average volume of 984,527. The firm has a 50-day moving average price of $20.59 and a 200-day moving average price of $21.71. Privia Health Group, Inc. has a 12 month low of $17.54 and a 12 month high of $30.15. The stock has a market cap of $2.18 billion, a price-to-earnings ratio of 96.74, a PEG ratio of 2.47 and a beta of 0.81.

Privia Health Group (NASDAQ:PRVA - Get Free Report) last posted its quarterly earnings data on Tuesday, February 27th. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.02). Privia Health Group had a return on equity of 3.97% and a net margin of 1.39%. The company had revenue of $440.80 million during the quarter, compared to the consensus estimate of $425.81 million. During the same quarter last year, the firm earned $0.14 EPS. The business's revenue for the quarter was up 21.0% on a year-over-year basis. Equities analysts expect that Privia Health Group, Inc. will post 0.26 EPS for the current year.

Insider Buying and Selling

In other Privia Health Group news, CFO David Mountcastle sold 3,933 shares of the business's stock in a transaction dated Tuesday, April 2nd. The shares were sold at an average price of $17.77, for a total transaction of $69,889.41. Following the sale, the chief financial officer now directly owns 262,279 shares of the company's stock, valued at approximately $4,660,697.83. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Privia Health Group news, Director William M. Sullivan sold 9,951 shares of the stock in a transaction that occurred on Wednesday, January 24th. The shares were sold at an average price of $23.03, for a total transaction of $229,171.53. Following the transaction, the director now owns 5,464,533 shares in the company, valued at approximately $125,848,194.99. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO David Mountcastle sold 3,933 shares of Privia Health Group stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an average price of $17.77, for a total transaction of $69,889.41. Following the completion of the transaction, the chief financial officer now directly owns 262,279 shares in the company, valued at $4,660,697.83. The disclosure for this sale can be found here. Company insiders own 57.60% of the company's stock.

Privia Health Group Company Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.